

ASX ANNOUNCEMENT

11 September 2017

BRONSON GROUP LTD APPOINTS KEY MEDICAL MARIJUANA CONSULTANT AS MANAGING DIRECTOR

- Strengthens experience and knowledge within the medical marijuana industry with the appointment of Amit Edri as Chief Executive Officer and Managing Director
- Mr Amit Edri brings a wealth of experience as COO of the largest medical cannabis company in Israel.

Bronson Group Ltd (ASX:BGR) (**BGR** or the **Company**) is pleased to announce that it has further strengthened its growth strategy following the execution of a Consultancy Services Agreement (**Agreement**) with Canigma A.L. Ltd (**Canigma** or the **Consultant**) (an entity incorporated in Israel) and Mr Amit Edri (**Nominated Person**).

Under the **Agreement**, Mr Edri is to be appointed as Chief Executive Officer and Managing Director of the Company.

Mr Edri was the COO of the largest medical cannabis processor in Israel – Bazelet group. Prior to joining the Bazelet Group, Mr Edri built a medical cannabis company- Canigma, from scratch.

As Founder and CEO of Canigma, he drove strategic initiatives of the start-up company; fused the business, financial, and technology interests of the company into cohesive operations; and led the business through market unpredictability, cutthroat competition and economic turmoil. His proficiency in building and restructuring medical cannabis business operations, and organisation culture speaks for itself.

The appointment of Mr Edri follows on from the Company's announcement on entering into a Binding Heads of Agreement in relation to the acquisition of all the shares in Pharmaceutical Development Company (Pty) Ltd.

The Consultant's remuneration is set out in Annexure A.

Ends

Contact:

Stephen Buckley
Company Secretary
Telephone: +61 (0)8 6189 1155

ANNEXURE A

Remuneration

The terms of the Agreement with the Consultant and the Nominated Person are:

- Prior to the Company successfully relisting its securities on ASX – a monthly fee of A\$ 7,482; and
- After the Company has successfully relisted its securities on ASX – a monthly fee of A\$ 14,964;
- An equity package to be determined by the Board, and which will be subject to Shareholder approval;
- Entitlement to be reimbursed for all reasonable expenses incurred in the performance of their duties plus any and all taxes applicable in connections with such reimbursement;
- Reimbursement of all reasonable relocation expenses should the Nominated Person need to move to Australia within the first six months of the Company successfully being relisted on ASX; and
- The fee will be reviewed annually by the Board.

Termination

Upon termination by the Company, the Company is only required to pay that fee which would otherwise be payable to the Consultant each month over the Company Notice Period. The Company Notice Periods are as are as follows:

- Prior to the Company successfully relisting its securities on ASX – one month;
- After the Company has successfully relisted its securities on ASX – six months.